{"protocolSection": {"identificationModule": {"nctId": "NCT01290874", "orgStudyIdInfo": {"id": "2010p001898"}, "organization": {"fullName": "Brigham and Women's Hospital", "class": "OTHER"}, "briefTitle": "Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)", "officialTitle": "Blacks and Exacerbations on LABA vs. Tiotropium (BELT)", "acronym": "BELT"}, "statusModule": {"statusVerifiedDate": "2018-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-03-30"}, "primaryCompletionDateStruct": {"date": "2013-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-12-28", "studyFirstSubmitQcDate": "2011-02-04", "studyFirstPostDateStruct": {"date": "2011-02-07", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-03-06", "resultsFirstSubmitQcDate": "2018-03-28", "resultsFirstPostDateStruct": {"date": "2018-03-30", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-03-28", "lastUpdatePostDateStruct": {"date": "2018-03-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Elliot Israel, MD", "investigatorTitle": "Director of the Asthma Research Center", "investigatorAffiliation": "Brigham and Women's Hospital"}, "leadSponsor": {"name": "Brigham and Women's Hospital", "class": "OTHER"}, "collaborators": [{"name": "Olmsted Medical Center", "class": "OTHER"}, {"name": "American Academy of Family Physicians National Research Network", "class": "NETWORK"}, {"name": "Baim Institute for Clinical Research", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "We are doing this study to learn how genes affect the way that people, specifically Black people, respond to treatment for asthma. Recent studies suggest that people respond differently to some asthma medications (eg Serevent, Foradil). Some people feel better when they use these inhalers, but others may not, and some people get worse. It seems that this difference shows up more often in Blacks than in Whites, which is why we are looking for Black subjects for this study. In all people, this difference seems to depend on their genes or DNA. This study is comparing the use of long acting asthma medications (Serevent, Foradil) to Tiotropium (Spiriva) for the treatment of asthma. Spiriva is used to treat chronic obstructive pulmonary disease (COPD). This study will help to see if this medication is also useful for treating asthma and whether it works better for some people than the current asthma medications.", "detailedDescription": "Asthma is a chronic respiratory disease that affects over 22 million people in the United States. Asthma produces 500,000 hospital admissions and accounts for 10.1 million days of lost work in adults annually. Asthma has been designated a priority condition of the Effective Health Care Program.\n\nBlacks bear a disproportionate burden of asthma morbidity and mortality. In its 2005 report on ethnic disparities in health care, AHRQ identified hospital admissions for asthma as the second largest disparity in quality of health care for Blacks vs. Caucasians.\n\nLong-acting beta-agonists (LABAs) produce extended increases in airway caliber among patients with asthma via action at the beta2-adrenergic receptor (ADRB2). Adding a LABA to an inhaled corticosteroid controller medication (ICS), can decrease asthma symptoms for many individuals and appears to decrease asthma exacerbations. LABA/ICS has become the most commonly prescribed ICS containing medication.\n\nDrugs acting at ADRB2, including LABAs, have been associated with rare loss of long-term asthma control and increased serious adverse outcomes including death and respiratory failure, even when used with ICS. The risk appears four to five-fold greater in Blacks than non-Black patients with asthma.\n\nConsensus guidelines recommend LABAs be added to ICS in those not completely controlled on ICS alone. These recommendations are based on weighing data on the benefit demonstrated in the general population vs. the rare risk of serious adverse outcomes and balancing the apparent benefits vs. the risks of LABAs (Kramer 2009). However, it appears that LABA/ICS may be significantly less effective in Blacks than Caucasians. Comparison of studies with LABA/ICS in Blacks vs. studies where Blacks were a small minority suggests that Blacks may have much less benefit than other racial groups. Additionally, recent data (Wechsler 2009) suggest that a polymorphism at the 16th position of the ADRB2 gene identifies a group of Blacks (those homozygous for arginine (Arg16Arg)) in whom the response of adding a LABA to an ICS is further diminished. This polymorphism is present in \\~20% of US Blacks."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Blacks", "LABA", "Tiotropium", "Spiriva", "African American", "Serevent", "salmeterol", "Foradil", "formoterol", "Advair", "Symbicort", "Dulera"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 1070, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Tiotropium", "type": "EXPERIMENTAL", "description": "Tiotropium bromide will be evaluated as a treatment for asthma.", "interventionNames": ["Drug: Tiotropium"]}, {"label": "Salmeterol or Formoterol", "type": "ACTIVE_COMPARATOR", "description": "Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.", "interventionNames": ["Drug: Salmeterol", "Drug: Formoterol"]}], "interventions": [{"type": "DRUG", "name": "Tiotropium", "description": "Tiotropium bromide 18 mcg once daily for one year of treatment.", "armGroupLabels": ["Tiotropium"], "otherNames": ["Spiriva"]}, {"type": "DRUG", "name": "Salmeterol", "description": "Salmeterol 50 mcg twice daily for one year of treatment.", "armGroupLabels": ["Salmeterol or Formoterol"], "otherNames": ["Serevent"]}, {"type": "DRUG", "name": "Formoterol", "description": "Formoterol 12 mcg twice daily for one year", "armGroupLabels": ["Salmeterol or Formoterol"], "otherNames": ["Foradil"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Time to Asthma Exacerbation (Mean Number of Exacerbations/Person-year)", "description": "We summarize the survival experience using mean number of exacerbations/person-year and compare it using the log-rank test comparing kaplan-meier survival curve.", "timeFrame": "evaluated monthly (on average) via questionnaire for 12 months"}], "secondaryOutcomes": [{"measure": "Change in FEV1", "description": "Average change in lung function (FEV1) evaluated by spirometry per participant over 12 months", "timeFrame": "from baseline to 12 months"}, {"measure": "Change in Asthma Control Questionnaire (ACQ)", "description": "Average Change in Asthma Control Score Per Participant Over 12 Months Using the Asthma Control Questionnaire (ACQ).\n\nThe ACQ has six questions regarding symptoms, rescue short-acting \u03b2-agonist use and one about FEV1 % predicted. A 7-point scale (0 = no impairment, 6 = maximum impairment) is used for each question and the ACQ score is the mean value of these questions - hence between 0 (totally controlled) and 6 (severely uncontrolled).", "timeFrame": "from baseline to 12 months"}, {"measure": "Change in Asthma Quality of Life (AQLQ)", "description": "Average Change in Asthma Quality of Life Score Per Participant Over 12 Months Using the Asthma Quality of Life Questionnaire (AQLQ).\n\nThe AQLQ has 32 questions in four domains (symptoms, activity limitation, emotional function, and environmental stimuli) and measures the functional problems that are troublesome to individuals with asthma. Symptoms (11 items), Activity Limitation (12 items, 5 of which are individualized), Emotional Function (5 items), and Environmental Exposure (4 items); 7-point Likert scale (7 = not impaired at all - 1 = severely impaired); scores range 1-7, with higher scores indicating better quality of life.", "timeFrame": "from baseline to 12 months"}, {"measure": "Change in Asthma Symptom Utility Index (ASUI)", "description": "Average Change in Asthma Symptom Utility Score Per Participant Over 12 Months Using the Asthma Symptom Utility Index (ASUI).\n\nThe ASUI is an 11-item preference-based outcome measure used in clinical trials and cost-effectiveness studies for asthma and is designed to assess the frequency and severity of cough, wheeze, dyspnea, nighttime awakenings, and side effects, weighted according to patient preferences.\n\n4-point Likert scale to assess frequency (not at all, 1 to 3 days, 4 to 7 days, and 8 to 14 days) and severity (not applicable, mild, moderate and severe); scores range from 0 (worst possible symptoms) to 1 (no symptoms).", "timeFrame": "from baseline to 12 months"}, {"measure": "Change in Symptom-Free Day Questionnaire (SFDQ)", "description": "Average Change in Symptom-Free Days Per Participant Over 12 Months Using the Symptom-Free Day Questionnaire (SFDQ).\n\nThe asthma symptom free day questionnaire (SFDQ) quantifies the number of days with neither daytime nor nighttime asthma symptoms, nor awakenings due to asthma symptoms.", "timeFrame": "from baseline to 12 months"}, {"measure": "Change in Rescue Medication Use", "description": "Average Change in Rescue Medication Use Per Participant Over 12 Months. Monthly questionnaires will evaluate the amount of rescue medication subjects have used on average, measured in puffs per day.", "timeFrame": "from baseline to 12 months"}, {"measure": "Change in Moderate Asthma Deterioration", "description": "Average Change in Moderate Asthma Deterioration Per Participant Over 12 Months. The definition of a moderate asthma deterioration should include one or more of the following: deterioration in symptoms, deterioration in lung function, or increased rescue bronchodilator use. These features should last for 2 days or more, but not be severe enough to warrant systemic corticosteroid use and/or hospitalization.", "timeFrame": "from baseline to 12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Black (self-identified, with at least one biological parent identified as Black)\n2. Male and female subjects, ages 18-75\n3. Ability to provide informed consent\n4. Clinical history consistent with asthma for \\> 1 year.\n5. Ability to perform pulmonary function tests\n6. FEV1 \\> 40% of predicted\n7. Receiving inhaled corticosteroids (ICS)/LABA combination therapy, or ICS moderate dose monotherapy and baseline ACQ\\>1.25\n8. Non-smoker for past year (total lifetime smoking history \\< 10 pack-years)\n\nExclusion Criteria:\n\n1. Use of greater than the equivalent of 1000 mcg inhaled fluticasone daily\n2. Chronic use of oral corticosteroids or Anti IgE for asthma\n3. Lung disease other than asthma or diagnosis of vocal cord dysfunction.\n4. Significant medical illness (other than asthma) that is not stable.\n5. Pregnancy or lactation or an unwillingness to maintain effective birth control.\n6. History of a significant exacerbation of asthma or respiratory tract infection in the prior 4 weeks\n7. History of life-threatening asthma requiring treatment with intubation and mechanical ventilation within 5 years.\n8. Hypo sensitization therapy other than an established maintenance regimen.\n9. Use of inhaled anticholinergic therapy (ipratropium, tiotropium) in prior month\n10. Known contraindication to inhaled tiotropium e.g. narrow angle glaucoma, history of bladder neck obstruction or significant symptoms related to prostatic hypertrophy.\n11. Inability to speak and read English.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Elliot Israel, MD", "affiliation": "Brigham and Women's Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Edward Waters College Medical Center (Mayo)", "city": "Jacksonville", "state": "Florida", "zip": "32209", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Urban Family Practice", "city": "Marietta", "state": "Georgia", "zip": "30067", "country": "United States", "geoPoint": {"lat": 33.9526, "lon": -84.54993}}, {"facility": "Albany Area Primary Healthcare, Inc", "city": "Newton", "state": "Georgia", "zip": "39870", "country": "United States", "geoPoint": {"lat": 31.31296, "lon": -84.33574}}, {"facility": "Northwestern University", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Wayne State University", "city": "Detroit", "state": "Michigan", "zip": "48201", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "G.A. Carmichael F.H.C.", "city": "Canton", "state": "Mississippi", "zip": "39046", "country": "United States", "geoPoint": {"lat": 32.61264, "lon": -90.03675}}, {"facility": "Swope Parkway Health Center", "city": "Kansas City", "state": "Missouri", "zip": "64130", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Montefiore Medical Group", "city": "Bronx", "state": "New York", "zip": "10462", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "UNYNET - Jefferson Family Medicine", "city": "Buffalo", "state": "New York", "zip": "14215", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}, {"facility": "Carolinas Medical Center - NorthEast (Lovelace)", "city": "Kannapolis", "state": "North Carolina", "zip": "28081", "country": "United States", "geoPoint": {"lat": 35.48736, "lon": -80.62173}}, {"facility": "Cleveland Clinic", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Family Medicine Occupational Health Center", "city": "Shaker Heights", "state": "Ohio", "zip": "44120", "country": "United States", "geoPoint": {"lat": 41.47394, "lon": -81.53707}}, {"facility": "BJHCHS - Hardeeville Medical Center", "city": "Ridgeland", "state": "South Carolina", "zip": "29936", "country": "United States", "geoPoint": {"lat": 32.48074, "lon": -80.98039}}]}, "referencesModule": {"references": [{"pmid": "26505596", "type": "RESULT", "citation": "Wechsler ME, Yawn BP, Fuhlbrigge AL, Pace WD, Pencina MJ, Doros G, Kazani S, Raby BA, Lanzillotti J, Madison S, Israel E; BELT Investigators. Anticholinergic vs Long-Acting beta-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial. JAMA. 2015 Oct 27;314(16):1720-30. doi: 10.1001/jama.2015.13277."}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects on combination ICS/LABA were switched to equivalent-dose ICS monotherapy at the same time they were assigned to the Tiotropium vs. LABA arm of the study.", "recruitmentDetails": "Initial enrollment began March 30, 2011 at the Asthma Research Center at Brigham and Women's Hospital. Subjects were recruited with print advertisements, internet postings, physician referrals, and by contacting patients in databases who asked to be contacted for studies.", "groups": [{"id": "FG000", "title": "Tiotropium", "description": "Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment."}, {"id": "FG001", "title": "Salmeterol or Formoterol", "description": "Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.\n\nSalmeterol: Salmeterol 50 mcg twice daily for one year of treatment.\n\nFormoterol: Formoterol 12 mcg twice daily for one year"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "532"}, {"groupId": "FG001", "numSubjects": "538"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "122"}, {"groupId": "FG001", "numSubjects": "134"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "410"}, {"groupId": "FG001", "numSubjects": "404"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Tiotropium", "description": "Tiotropium bromide will be evaluated as a treatment for asthma.\n\nTiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment."}, {"id": "BG001", "title": "Salmeterol or Formoterol", "description": "Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.\n\nSalmeterol: Salmeterol 50 mcg twice daily for one year of treatment.\n\nFormoterol: Formoterol 12 mcg twice daily for one year"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "532"}, {"groupId": "BG001", "value": "538"}, {"groupId": "BG002", "value": "1070"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.2", "spread": "12.6"}, {"groupId": "BG001", "value": "45.1", "spread": "12.6"}, {"groupId": "BG002", "value": "45.15", "spread": "12.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "405"}, {"groupId": "BG001", "value": "408"}, {"groupId": "BG002", "value": "813"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "130"}, {"groupId": "BG002", "value": "257"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "67"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "501"}, {"groupId": "BG001", "value": "502"}, {"groupId": "BG002", "value": "1003"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "532"}, {"groupId": "BG001", "value": "538"}, {"groupId": "BG002", "value": "1070"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Time to Asthma Exacerbation (Mean Number of Exacerbations/Person-year)", "description": "We summarize the survival experience using mean number of exacerbations/person-year and compare it using the log-rank test comparing kaplan-meier survival curve.", "populationDescription": "intention-to-treat", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "event per person-year", "timeFrame": "evaluated monthly (on average) via questionnaire for 12 months", "groups": [{"id": "OG000", "title": "Tiotropium", "description": "Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment."}, {"id": "OG001", "title": "Salmeterol or Formoterol", "description": "Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.\n\nSalmeterol: Salmeterol 50 mcg twice daily for one year of treatment.\n\nFormoterol: Formoterol 12 mcg twice daily for one year"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "532"}, {"groupId": "OG001", "value": "538"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.37", "lowerLimit": "0.32", "upperLimit": "0.43"}, {"groupId": "OG001", "value": "0.42", "lowerLimit": "0.36", "upperLimit": "0.48"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.31", "statisticalMethod": "Log Rank"}]}, {"type": "SECONDARY", "title": "Change in FEV1", "description": "Average change in lung function (FEV1) evaluated by spirometry per participant over 12 months", "populationDescription": "255 and 253 participants are missing data on change in FEV1 in the Tiotropium and Salmeterol or Formoterol arms, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters", "timeFrame": "from baseline to 12 months", "groups": [{"id": "OG000", "title": "Tiotropium", "description": "Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment."}, {"id": "OG001", "title": "Salmeterol or Formoterol", "description": "Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.\n\nSalmeterol: Salmeterol 50 mcg twice daily for one year of treatment.\n\nFormoterol: Formoterol 12 mcg twice daily for one year"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "277"}, {"groupId": "OG001", "value": "285"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.018", "lowerLimit": "-0.047", "upperLimit": "0.012"}, {"groupId": "OG001", "value": "0.003", "lowerLimit": "-0.026", "upperLimit": "0.031"}]}]}]}, {"type": "SECONDARY", "title": "Change in Asthma Control Questionnaire (ACQ)", "description": "Average Change in Asthma Control Score Per Participant Over 12 Months Using the Asthma Control Questionnaire (ACQ).\n\nThe ACQ has six questions regarding symptoms, rescue short-acting \u03b2-agonist use and one about FEV1 % predicted. A 7-point scale (0 = no impairment, 6 = maximum impairment) is used for each question and the ACQ score is the mean value of these questions - hence between 0 (totally controlled) and 6 (severely uncontrolled).", "populationDescription": "334 and 326 participants are missing data on ACQ in the Tiotropium and Salmeterol or Formoterol arms, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "from baseline to 12 months", "groups": [{"id": "OG000", "title": "Tiotropium", "description": "Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment."}, {"id": "OG001", "title": "Salmeterol or Formoterol", "description": "Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.\n\nSalmeterol: Salmeterol 50 mcg twice daily for one year of treatment.\n\nFormoterol: Formoterol 12 mcg twice daily for one year"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "212"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.70", "lowerLimit": "-0.81", "upperLimit": "-0.60"}, {"groupId": "OG001", "value": "-0.66", "lowerLimit": "-0.77", "upperLimit": "-0.55"}]}]}]}, {"type": "SECONDARY", "title": "Change in Asthma Quality of Life (AQLQ)", "description": "Average Change in Asthma Quality of Life Score Per Participant Over 12 Months Using the Asthma Quality of Life Questionnaire (AQLQ).\n\nThe AQLQ has 32 questions in four domains (symptoms, activity limitation, emotional function, and environmental stimuli) and measures the functional problems that are troublesome to individuals with asthma. Symptoms (11 items), Activity Limitation (12 items, 5 of which are individualized), Emotional Function (5 items), and Environmental Exposure (4 items); 7-point Likert scale (7 = not impaired at all - 1 = severely impaired); scores range 1-7, with higher scores indicating better quality of life.", "populationDescription": "242 and 239 participants are missing data on AQLQ in the Tiotropium and Salmeterol or Formoterol arms, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "from baseline to 12 months", "groups": [{"id": "OG000", "title": "Tiotropium", "description": "Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment."}, {"id": "OG001", "title": "Salmeterol or Formoterol", "description": "Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.\n\nSalmeterol: Salmeterol 50 mcg twice daily for one year of treatment.\n\nFormoterol: Formoterol 12 mcg twice daily for one year"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "290"}, {"groupId": "OG001", "value": "299"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "lowerLimit": "0.88", "upperLimit": "1.12"}, {"groupId": "OG001", "value": "1.02", "lowerLimit": "0.90", "upperLimit": "1.14"}]}]}]}, {"type": "SECONDARY", "title": "Change in Asthma Symptom Utility Index (ASUI)", "description": "Average Change in Asthma Symptom Utility Score Per Participant Over 12 Months Using the Asthma Symptom Utility Index (ASUI).\n\nThe ASUI is an 11-item preference-based outcome measure used in clinical trials and cost-effectiveness studies for asthma and is designed to assess the frequency and severity of cough, wheeze, dyspnea, nighttime awakenings, and side effects, weighted according to patient preferences.\n\n4-point Likert scale to assess frequency (not at all, 1 to 3 days, 4 to 7 days, and 8 to 14 days) and severity (not applicable, mild, moderate and severe); scores range from 0 (worst possible symptoms) to 1 (no symptoms).", "populationDescription": "257 and 265 participants are missing data on ASUI in the Tiotropium and Salmeterol or Formoterol arms, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "from baseline to 12 months", "groups": [{"id": "OG000", "title": "Tiotropium", "description": "Tiotropium bromide will be evaluated as a treatment for asthma.\n\nTiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment."}, {"id": "OG001", "title": "Salmeterol or Formoterol", "description": "Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.\n\nSalmeterol: Salmeterol 50 mcg twice daily for one year of treatment.\n\nFormoterol: Formoterol 12 mcg twice daily for one year"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "273"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "lowerLimit": "0.09", "upperLimit": "0.13"}, {"groupId": "OG001", "value": "0.10", "lowerLimit": "0.08", "upperLimit": "0.13"}]}]}]}, {"type": "SECONDARY", "title": "Change in Symptom-Free Day Questionnaire (SFDQ)", "description": "Average Change in Symptom-Free Days Per Participant Over 12 Months Using the Symptom-Free Day Questionnaire (SFDQ).\n\nThe asthma symptom free day questionnaire (SFDQ) quantifies the number of days with neither daytime nor nighttime asthma symptoms, nor awakenings due to asthma symptoms.", "populationDescription": "The instrument used to collect data proved to be unreliable. The statistic for internal consistency demonstrated less than 30% internal consistency.", "reportingStatus": "POSTED", "timeFrame": "from baseline to 12 months", "groups": [{"id": "OG000", "title": "Tiotropium", "description": "Tiotropium bromide will be evaluated as a treatment for asthma.\n\nTiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment."}, {"id": "OG001", "title": "Salmeterol or Formoterol", "description": "Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.\n\nSalmeterol: Salmeterol 50 mcg twice daily for one year of treatment.\n\nFormoterol: Formoterol 12 mcg twice daily for one year"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change in Rescue Medication Use", "description": "Average Change in Rescue Medication Use Per Participant Over 12 Months. Monthly questionnaires will evaluate the amount of rescue medication subjects have used on average, measured in puffs per day.", "populationDescription": "335 and 328 participants are missing data on rescue medication use in the Tiotropium and Salmeterol or Formoterol arms, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "from baseline to 12 months", "groups": [{"id": "OG000", "title": "Tiotropium", "description": "Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment."}, {"id": "OG001", "title": "Salmeterol or Formoterol", "description": "Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.\n\nSalmeterol: Salmeterol 50 mcg twice daily for one year of treatment.\n\nFormoterol: Formoterol 12 mcg twice daily for one year"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "210"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.92", "lowerLimit": "-1.27", "upperLimit": "-0.57"}, {"groupId": "OG001", "value": "-0.97", "lowerLimit": "-1.32", "upperLimit": "-0.63"}]}]}]}, {"type": "SECONDARY", "title": "Change in Moderate Asthma Deterioration", "description": "Average Change in Moderate Asthma Deterioration Per Participant Over 12 Months. The definition of a moderate asthma deterioration should include one or more of the following: deterioration in symptoms, deterioration in lung function, or increased rescue bronchodilator use. These features should last for 2 days or more, but not be severe enough to warrant systemic corticosteroid use and/or hospitalization.", "populationDescription": "Inadequate baseline data was collected so that the change in this variable could not be assessed.", "reportingStatus": "POSTED", "timeFrame": "from baseline to 12 months", "groups": [{"id": "OG000", "title": "Tiotropium", "description": "Tiotropium bromide will be evaluated as a treatment for asthma.\n\nTiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment."}, {"id": "OG001", "title": "Salmeterol or Formoterol", "description": "Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.\n\nSalmeterol: Salmeterol 50 mcg twice daily for one year of treatment.\n\nFormoterol: Formoterol 12 mcg twice daily for one year"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse events were reported from the time of patient enrollment to up to 18 months after study completion.", "eventGroups": [{"id": "EG000", "title": "Tiotropium", "description": "Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment.", "seriousNumAffected": 84, "seriousNumAtRisk": 532, "otherNumAffected": 338, "otherNumAtRisk": 532}, {"id": "EG001", "title": "Salmeterol or Formoterol", "description": "Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.\n\nSalmeterol: Salmeterol 50 mcg twice daily for one year of treatment.\n\nFormoterol: Formoterol 12 mcg twice daily for one year", "seriousNumAffected": 69, "seriousNumAtRisk": 538, "otherNumAffected": 342, "otherNumAtRisk": 538}], "seriousEvents": [{"term": "Acute Myocardial Infarction", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Angina Pectoris", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Angina Unstable", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Cardiac Disorder", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Cardiac Failure Congestive", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 538}]}, {"term": "Cardiomyopathy", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Cardiopulmonary Failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Coronary Artery Disease", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Coronary Artery Occlusion", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Dysponea", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 538}]}, {"term": "Goitre", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Abdominal Distension", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Abdominal Hernia", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Diverticulum Intestinal", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Hiatus Hernia", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Impaired Gastric Emptying", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Rectal Haemorrhage", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Small Intestinal Obstruction", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Upper Gastrointestinal Haemorrhage", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Chest Discomfort", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Chest Pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 538}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 538}]}, {"term": "Oedema", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Oedema Peripheral", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Gallbladder Disorder", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Anaphylactic Reaction", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Gastrointestinal bacterial infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Localized Infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Wound infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Incisional hernia", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 538}]}, {"term": "Costochondritis", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Rheumatoid arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Brain neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Endometrial cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Cerebral cyst", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 538}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Dysarthria", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Hemiparesis", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Loss of consciousness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Myelopathy", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Mental status change", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Menorrhagia", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Postmenopausal haemorrhage", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Vaginal haemorrhage", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Bronchitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 538}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Hypoxia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Blister", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 538}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Vasculitis", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 538}]}, {"term": "Disease Progression", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 538}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 30, "numAffected": 30, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 23, "numAffected": 23, "numAtRisk": 538}]}], "otherEvents": [{"term": "Disease Progression", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 211, "numAffected": 211, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 203, "numAffected": 203, "numAtRisk": 538}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 127, "numAffected": 127, "numAtRisk": 532}, {"groupId": "EG001", "numEvents": 139, "numAffected": 139, "numAtRisk": 538}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Elliot Israel", "organization": "Brigham and Women's Hospital", "email": "eisrael@partners.org", "phone": "6177328201"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000069447", "term": "Tiotropium Bromide"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000010276", "term": "Parasympatholytics"}, {"id": "D000018680", "term": "Cholinergic Antagonists"}, {"id": "D000018678", "term": "Cholinergic Agents"}], "browseLeaves": [{"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M5241", "name": "Bromides", "relevance": "LOW"}, {"id": "M416", "name": "Tiotropium Bromide", "asFound": "Melanoma", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M249", "name": "Fluticasone-Salmeterol Drug Combination", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M13189", "name": "Parasympatholytics", "relevance": "LOW"}, {"id": "M20760", "name": "Cholinergic Antagonists", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}]}}, "hasResults": true}